Enzon NDA
Executive Summary
Enzon NDA: Firm's first NDA filing is for PEG-adenosine deaminase (PEG-ADA), for treatment of severe combined immunodeficiency disease in children. "PEG-ADA is the first of four Enzon products currently in clinical development for which NDA's are expected to be filed in the next one to three years," company said.